189 results about "Nephritis" patented technology

The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the complement component C3 gene (C3). The invention also relates to methods of using such RNAi agents to inhibit expression of a C3 gene and to methods of preventing and treating a C3-associated disorder, e.g., cold agglutinin disease (CAD), warm autoimmune hemolytic anemia, and paroxysmal nocturnal hemoglobinuria (PNH), lupis nephritis (LN), bullous pemphigoid, Pemphigus, e.g., Pemphigus vulgaris (PV) and Pemphigus foliaceus (PF), and C3 glomerulopathy.

The invention discloses a method for constructing a differential diagnosis model for lupus nephritis and membranous nephropathy, and belongs to the technical field of intelligent medical treatment. The modeling method comprises the following steps: S1, respectively collecting flow cytometry detection data of lupus nephritis patients and healthy control personnel; s2, performing data cleaning and conversion on the flow cytometry detection data, and converting non-numerical features into digits; carrying out implication on the missing value by adopting a k nearest neighbor algorithm from an implication packet; s3, random sampling is carried out on the cleaned and converted data set, and samples are divided into a training set and a verification set according to the proportion of 7: 3; s4, dividing a training subset and a test set from the training set, and iteratively selecting the types of cells incorporated into the constructed model as pDC, CD4T, effector CD4T, Th2, CD8T, CD38 + HLA-DR + CD8T, and CD38 + PD-1 + CD8T by adopting an RFE method, wherein the types of the cells incorporated into the constructed model are pDC, CD4T, effector CD4T, Th2, CD8T, CD38 + HLA-DR + CD8T and CD38 + PD-1 + CD8T; and S5, performing a classification task by adopting TabPFNClassifier, performing training from features selected from the training data set, then evaluating the performance of the model, performing model training by utilizing detection data, and performing evaluation to construct a lupus nephritis prediction model with high accuracy.

The invention relates to a flavonoid active fraction of an Abelmoschi corolla, a preparation method and an application thereof, and belongs to the field of traditional Chinese pharmaceutics. A high-purity Abelmoschi corolla flavonoid active fraction is prepared, which is found to have better therapeutic activity for kidney disease, and especially have a significant therapeutic effect for diabetic kidney disease and lupus nephritis, or contrast-induced kidney injury and eye diseases. Meanwhile, the Abelmoschi corolla flavonoid active fraction described in the invention also has good safety.

Provided is a circular RNA encoding CARs and the use thereof to create immune cells that target specific diseases, e. g., lymphoma, multiple myeloma and leukemia and auntoimmune diseases, such as systemic lupus erythematousus, lupus nephritis and myasthenia gravis.

The invention provides an application of a reagent for detecting an effector CD4 + T cell in peripheral blood of a subject in preparation of a product for diagnosing membranous nephropathy, lupus nephritis or ANCA-related vasculitis. The invention also provides an application of the effector CD4 + T cell in peripheral blood in preparation of a diagnostic model for diagnosing membranous nephropathy, lupus nephritis or ANCA-related vasculitis. The marker is detected through flow cytometry, and the result shows that the Ejector CD4 + T cell is remarkably increased in a patient with membranous nephropathy, can effectively distinguish membranous nephropathy from healthy control (verification set AUC 0.8098), can assist in identifying membranous nephropathy, lupus nephritis (verification set AUC 0.8686) and ANCA-related vasculitis (verification set AUC 0.8968), and the level of the Ejector CD4 + T cell is related to whether membranous nephropathy is difficult to treat or not.

The invention discloses a lupus nephritis marker and application thereof, and belongs to the technical field of biomarkers. The marker for the lupus nephritis, disclosed by the invention, comprises one or more of CD8, CD38 and PD-1. By detecting specific cell surface markers in patient blood, early diagnosis of LN is assisted in a minimally invasive mode, and based on deep comparative analysis of LN patients and healthy people, the specificity and sensitivity of the biomarkers in LN diagnosis are ensured through screening of the biomarkers. In the aspect of differential diagnosis, a clinician is assisted to distinguish LN from other types of kidney diseases, such as membranous nephropathy (MN) and anti-neutrophil cytoplasm antibody related vasculitis (AAV), by analyzing specific biomarker modes of different nephropathy. The dependence on kidney puncture is reduced, related potential risks and inconvenience are avoided, and meanwhile more accurate and timely diagnosis is provided for an SLE patient.

The present invention relates to a double-stranded siRNA analogue for inhibiting expression of mannan-binding lectin-related serine protease 2 (MASP2), and a preparation method and use thereof, the double-stranded siRNA analogue can inhibit expression of MASP2, and is used for preventing and / or treating MASP2-related diseases and symptoms, such as MASP2-related diseases and disorders. The diseases and symptoms comprise IgA nephropathy, membranous nephropathy, lupus nephritis, thrombotic microangiopathy, systemic lupus erythematosus and the like.

The application of phlorizin in the medicine for treating and / or preventing lupus nephritis, the molecular formula of phlorizin is C 21 H 24 O 10 , the application promotes the differentiation of regulatory T cells (Treg) by applying phlorizin to up-regulate the PI3K / Akt signal pathway, thereby reducing the symptoms of lupus nephritis, and provides an effective treatment method with less side effects. In the application, the traditional Chinese medicine monomer phlorizin can effectively promote the differentiation of Treg cells, and compared with compound traditional Chinese medicine, the use of single component has more advantages in drug efficacy control and efficacy evaluation. In addition, phlorizin is widely sourced, low in cost and non-toxic, and is very suitable for long-term treatment of lupus nephritis.

Disclosed herein is a method for treating immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) with the factor B inhibitor iptacopan or a pharmaceutically acceptable salt thereof (e.g., iptacopan hydrochloride).

The invention provides an antrodia camphorata sporocarp extract, which is prepared from the following raw materials in parts by weight: 20 to 24 parts of wild ganoderma lucidum extract, 8 to 12 parts of herba taraxaci and 8 to 12 parts of bolete. The antrodia camphorata sporocarp extract disclosed by the invention contains various physiologically active components such as triterpenoids, polysaccharides, superoxide disproportionated enzymes, adenosine, proteins (containing immune proteins), vitamins, trace elements, nucleic acid, lectin, amino acid, sterols, lignin, blood pressure stabilizing substances and the like; the traditional Chinese medicine composition can relieve various tumors such as hangover, gastrointestinal discomfort, heatstroke, hypertension, virus infection, diabetes mellitus, nephritis, liver cirrhosis and liver cancer, has the effects of resisting oxidation, resisting inflammation, inhibiting hypertension, protecting liver nerves, inhibiting tumor growth and the like, can bidirectionally regulate immunity and protect the liver, can also treat tumors at multiple targets, and has a wide application prospect. The discomfort of a patient in an anti-tumor process is reduced.

Described herein are methods of treating immune complex mediated membrane proliferative glomerulonephritis (IC-MPGN) with a factor B inhibitor ipropam or a pharmaceutically acceptable salt thereof, e.g., ipropam hydrochloride.

The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) remain poorly understood. A key question is how parietal epithelial cells (PECs) invade glomerular capillaries, thereby promoting injury and kidney failure. Here the inventors show that expression of the tetraspanin CD9 increases markedly in PECs in mouse models of CGN and FSGS, and in kidneys from individuals diagnosed with these diseases. Cd9 gene targeting in PECs prevents glomerular damage in CGN and FSGS mouse models. Mechanistically, CD9 deficiency prevents the oriented migration of PECs into the glomerular tuft and their acquisition of CD44 and β1 integrin expression. These findings highlight a critical role for de novo expression of CD9 as a common pathogenic switch driving the PEC phenotype in CGN and FSGS, while offering a potential therapeutic avenue to treat these conditions. Accordingly, CD9 represents a reliable biomarker and as well as a biotargets in glomerulonephritides.

The application relates to methods for the diagnosis, treatment, and prevention of autoimmune and / or inflammatory disease such as systemic lupus erythematosus (SLE), lupus nephritis, IgA nephropathy, other types of glomerulonephritis.

The present invention belongs to the field of medicine and discloses the use of tubulointerstitial nephritis antigen-like protein 1 (TINAGL1) as a direct target for screening anti-hepatic fibrosis drugs. By using TINAGL1 as a direct target, target drugs that can bind to human TINAGL1 recombinant protein can be screened out. These target drugs have been proven to be able to reduce the increase in the level of the fibrosis factor COL1A1 in LX-2 cells induced by PDGF-BB and can achieve anti-hepatic fibrosis effects to varying degrees. At the same time, the present invention also discloses a screening method for anti-hepatic fibrosis drugs, new potential anti-hepatic fibrosis drugs, and new uses of compounds.

The application discloses a kind of biomarkers for evaluating systemic lupus erythematosus to lupus nephritis progression, prediction model and application, belong to lupus nephritis prediction technical field.The application provides a kind of for evaluating systemic lupus erythematosus to lupus nephritis progression prediction model, the prediction model is according to the ratio of biomarker CD8 / CD4 and the κ / λ ratio of naive B cell, carries out binary Logistic regression analysis, obtains LogitP value, by comparing the high and low of the LogitP value and critical value 0.66938, predicts systemic lupus erythematosus to lupus nephritis progression situation.The prediction model constructed in the application aims to identify the individuals in lupus patients who may develop into lupus nephritis.This innovative model not only provides important guidance in the diagnosis, prognosis prediction and efficacy evaluation of the disease, but also provides a new perspective for the clinical management of lupus nephritis.

The invention discloses a diagnostic marker for ANCA (Angiovasculitis) related vasculitis. It is found for the first time that the CD19 + CD38 + CD27-CD24 + cell can be used as the diagnosis marker of ANCA related vasculitis, and the diagnosis efficiency is high; in addition, it is found that the CD19 + CD38 + CD27-CD24 + cells can remarkably distinguish ANCA related vasculitis and membranous nephropathy or ANCA related vasculitis and lupus nephritis, a new direction is provided for diagnosis and subsequent treatment of ANCA related vasculitis, and the application has wide application prospects clinically.

The invention relates to the field of medical care informatics, and discloses a lupus nephritis condition monitoring system based on TWEAK and CD163 dynamic change, which comprises a data adaptation gateway module, a data rationality arbitration engine, a time sequence regularization engine module, a high-order feature extraction engine module and a risk layering module, the time sequence regularization engine module switches an interpolation or smoothing algorithm based on a qualitative result of the data rationality arbitration engine and a time domain where a data point is located so as to generate a continuous time function. Through the information processing architecture, the technical problem that sparse asynchronous original medical data is prone to being affected by outlier pollution and end point distortion is solved, and the accuracy of data processing is improved. The system reconstructs discrete data snapshots into continuous mathematical objects, provides a stable and analyzable technical basis for subsequent extraction of interpretable high-order dynamic features, and improves the credibility of clinical decision support.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

The present disclosure provides methods of treating or reducing the symptoms of glomerulonephritis in a subject.

The invention provides methods for treating or delaying progression of lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. The invention also provides methods for treating or delaying progression of rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) in an individual. In some embodiments, the methods comprise administering an effective amount of an anti-CD20 antibody.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to traditional Chinese medicine compound granules for treating lupus nephritis and a preparation method thereof. The formula of the traditional Chinese medicine compound granules comprises 25-35 parts of astragalus membranaceus, 8-12 parts of angelica sinensis, 8-12 parts of salvia miltiorrhiza, 25-35 parts of artemisia apiacea, 12-18 parts of caulis sinomenii, 25-35 parts of centella asiatica, 25-35 parts of raw malt and 25-35 parts of euonymus alatus. The medicinal materials are subjected to water extraction, extracting solutions are combined and concentrated into extract, maltodextrin, microcrystalline cellulose and soluble starch are selected as auxiliary materials to be dried and granulated, and the prepared traditional Chinese medicine compound granules are low in fine powder proportion, high in hardness and short in dissolution time. By adopting the dosage form of granules, not only are the characteristics of quick absorption and quick action of the decoction maintained, but also the defects of inconvenience in decoction, large dosage and easiness in mildewing during temporary use of the decoction are overcome, and the curative effect is remarkably improved.

To provide a method for treating a proteinuric kidney disease.SOLUTION: There is provided a method comprising administering a predetermined daily dosage of effective amounts of voclosporin over a projected treatment period of at least 24 weeks. The method further comprises: (a) assessing an estimated Glomerular Filtration Rate (eGFR) of a subject at at least a first time point and a second time point on different days within the treatment period; and (b) (i) when the eGFR of the subject decreases by more than a target % to below a predetermined value between the first and second time points, reducing the daily dosage by units of 7.9 mg BID or discontinuing the administration of voclosporin to the subject; (ii) when the eGFR of the subject decreases by less than the target % between the first and second time points, continuing to administer the same predetermined daily dosage of voclosporin to the subject.SELECTED DRAWING: Figure 1

The invention relates to the technical field of nephritis medicine, in particular to an AAGN disease metabolism marker, a kit and application of the AAGN disease metabolism marker. In the blood or urine metabolism marker, the blood metabolism marker is prepared from one or more of 6-methyl nicotinamide, hypo-sulphosarcosine, guanosine, allopurinol, 8-hydroxy-2 '-deoxyguanosine, triglyceride or lysophosphatidylcholine; the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl-leucyl-phenylalanine, alloandrosterone, enterodiphenol and p-coumarin, and the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl- The metabolic marker combination and the kit are used for evaluating the disease activity state of a patient suffering from ANCA-related glomerulonephritis (AAGN), and have good repeatability, stability and biological correlation.

The present disclosure relates to methods and compositions for the treatment of a mammalian subject suffering from lupus the method comprising, administering to said subject a therapeutically effective amount of an orthogonal CAR-T cell directed against a B-cell antigen in combination with an engineered orthogonal IL2 ligand that selectively activates orthogonal CAR T cell expressing an engineered orthogonal CD122 receptor. In some embodiments, the lupus is systemic lupus erythramatosis (SLE). In some embodiments, the lupus is lupus nephritis. In some embodiments the subject suffering from lupus is also suffering from cytopenia. In some embodiments the methods are practiced in the absence of prior lymphodepletion of the subject.

The present invention belongs to the field of biomedical technology and specifically discloses the use of a substance that inhibits the activity and / or expression of a CAPG gene or protein in preparing a product for treating renal fibrosis caused by renal injury. The present invention first discovered through research that CAPG is expressed at a low level in normal renal tissue, but its expression level is elevated in renal tissue of patients with acute renal injury, minimal change disease, IgA nephropathy, lupus nephritis, and diabetic nephropathy, indicating that CAPG expression may be involved in the occurrence and development of renal fibrosis caused by renal injury. Then, by constructing a CAPG knockout mouse model, it was found that knocking out CAPG can effectively reduce the progression of renal fibrosis. By culturing renal fibroblasts in vitro, it was found that silencing or knocking down CAPG can inhibit TGF-β-induced renal fibroblast activation. The research of the present invention is of great significance for the pathogenesis and treatment of renal injury or renal fibrosis.

The present invention relates to a pharmaceutical composition for treating chronic glomerulonephritis, its preparation method and application. The pharmaceutical composition is composed of Rhizoma Smilacis Glabrae Albae, Flos Abelmoschi Manihot, Herba Ephedrae Delavayi, Radix Saposhnikoviae Divaricatae, Ramulus Ulmi Pumilae, Herba Dichondrae Repentis, Rhizoma Corydalis Saxicolae, Radix Salviae Yunnanensis, and Radix Achyranthis Aspera. The preparation method is to first extract the above nine herbs with ethanol and then with water, and the mixed solution is concentrated to make a pharmaceutical preparation. The combined use of this pharmaceutical preparation and western medicine can improve the treatment effect of chronic glomerulonephritis, with a total effective rate reaching 84%. Moreover, it can significantly reduce the urinary protein and red blood cells in patients, showing a significant difference compared with the control group using western medicine alone. This indicates that it can effectively improve the clinical symptoms of patients, has no adverse reactions, has high safety, and has extremely high popularization value.

The present invention relates to a nanoparticle comprising a nanomaterial and at least a first ligand and a second ligand tethered to the nanoparticle. The present invention also relates to a nanoparticle for use as a medicament or diagnostic agent. The present invention also relates to a nanoparticle for use in a method for preventing or treating a disease selected from the group consisting of diabetic nephropathy, glomerulonephritis, glomerular VEGF A dysregulation, endothelial VEGF A dysregulation, diabetic retinopathy, rheumatoid arthritis, age-related macular degeneration and cancer, such as breast cancer. Furthermore, the present invention relates to a method of preparing a nanoparticle.

The present invention provides a serum exosomal tsRNA (tRNA-derived small RNA, tsRNA) biomarker, a probe and their applications for the diagnosis of lupus nephritis, belonging to the field of molecular biology; the biomarker is one or a combination of tRF-Thr-TGT-4-M3 and tRF-Tyr-GTA-1-M2; the exosomal tsRNA screened by the present invention is significantly highly expressed in the serum exosomes of lupus nephritis patients, has a good correlation with the clinical indicators of lupus nephritis, and can be used to identify whether SLE patients have kidney involvement; the biomarker can be used to prepare a diagnostic kit for the auxiliary early diagnosis of lupus nephritis in clinical practice.

The invention provides an application of a TRPML1 specific small-molecule inhibitor ML-SI3 in preparation of a medicine for treating or preventing nephritis. The TRPML1 specific small-molecule inhibitor ML-SI3 disclosed by the invention has the beneficial effects that the TRPML1 specific small-molecule inhibitor ML-SI3 disclosed by the invention can be used for remarkably reducing the titer level of an anti-dsDNA antibody in serum of an MRL / lpr lupus mouse; the urinary albumin / creatinine ratio level is reduced; the serum urea nitrogen level is reduced; the swelling degree of spleen and axillary lymph nodes is relieved; the kidney pathological change is improved; the compound has a comprehensive protection effect on nephritis of MRL / lpr lupus mice; the invention provides the application of the TRPML1 specific small-molecule inhibitor ML-SI3 in preparation of the medicine for treating or preventing nephritis, provides a new medicine for treating lupus nephritis, and has good market value and clinical application prospect.

Provided herein are methods for treating lupus nephritis using an effective amount of a human neonatal Fc receptor (FcRn) antagonist. Also provided herein are FcRn antagonists for use in treating lupus nephritis, and FcRn antagonists for use in the manufacture of medicaments for treating lupus nephritis.